Current Edition

a CSL Behring

CSL to buy Vifor for $11.7B in biopharma’s largest M&A deal this year

In a move to diversify its business, Australian biopharma CSL has agreed to acquire Vifor Pharma for $11.7 billion. The deal would give CSL—heavily dependent …

Continue Reading →
biomarker

Proteomics and Dimerix partner to improve the treatment of kidney disease

Australia-based Proteomics International (PI) has developed PromarkerD, a predictive and diagnostic test for diabetic kidney disease that measures a protein biomarker panel in the blood. …

Continue Reading →